John Minni, DO
Dermatology · Stuart, FLNPI 1144303009
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $1,234,584 of the $1,385,124 with a category attached, or 89.1%. It is spread thinly across 30 manufacturers, the largest accounting for just 16.4%. Among dermatology clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 2,023 payments — averaging $684.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$227K
- AbbVie$199K
- Janssen Scientific Affairs, LLC$162K
- Regeneron Healthcare Solutions, Inc.$147K
- UCB, Inc.$144K
- Sanofi$96K
- plus $410K from 24 others
What the payments were for
- Consulting fees$66,2485%
- Speaking & faculty fees$1,234,58489%
- Travel & lodging$41,4843%
- Food & beverage$41,3833%
- Education$1,4240%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 287 | $226,800 |
| AbbVie | 291 | $198,722 |
| Janssen Scientific Affairs, LLC | 125 | $162,202 |
| Regeneron Healthcare Solutions, Inc. | 223 | $147,228 |
| UCB, Inc. | 166 | $143,846 |
| Sanofi | 98 | $96,012 |
| Amgen(2 entities) | 115 | $77,139 |
| Galderma Laboratories, L.p. | 99 | $67,061 |
| Novartis | 82 | $59,495 |
| Incyte Corporation | 94 | $51,476 |
| E.r. Squibb & Sons, L.L.C. | 93 | $51,434 |
| LEO Pharma Inc. | 73 | $36,576 |
| Organon | 38 | $27,204 |
| Bristol Myers Squibb | 25 | $19,994 |
| Lilly USA, LLC | 23 | $10,484 |
| Pfizer | 26 | $5,214 |
| Dermavant Sciences, Inc. | 71 | $2,961 |
| Arcutis Biotherapeutics, Inc. | 61 | $504 |
| Sun Pharmaceutical Industries Inc. | 11 | $222 |
| Sanofi-aventis U.S. LLC | 2 | $119 |
| Almirall LLC | 5 | $94 |
| Dermira, Inc. | 3 | $66 |
| Genentech USA, Inc. | 3 | $65 |
| Mayne Pharma Commercial LLC | 2 | $53 |
| Boehringer Ingelheim | 2 | $44 |
| Verrica Pharmaceuticals Inc. | 1 | $24 |
| Smith+Nephew | 1 | $24 |
| Mylan Institutional Inc. | 1 | $22 |
| Biofrontera Inc. | 1 | $21 |
| VYNE Pharmaceuticals Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,385,124 in reported general payments places this provider in the 95th percentile of 1,147 dermatology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Skyrizi PenRisankizumab-Rzaa | 48 | $980,008 |
| TremfyaGuselkumab | 46 | $630,293 |
| Dupixent PenDupilumab | 151 | $596,533 |
| OdomzoSonidegib Phosphate | 34 | $423,849 |
| Bimzelx AutoinjectorBimekizumab-Bkzx | 23 | $346,761 |
| Dupixent SyringeDupilumab | 80 | $306,105 |
| SkyriziRisankizumab-Rzaa | 11 | $229,474 |
| SotyktuDeucravacitinib | 22 | $179,670 |
| Humira(Cf) PenAdalimumab | 13 | $165,234 |
| Humira PenAdalimumab | 17 | $136,756 |
| Cosentyx Sensoready (2 Pens)Secukinumab | 15 | $109,378 |
| OtezlaApremilast | 17 | $82,359 |
| AdbryTralokinumab-Ldrm | 18 | $68,198 |
| ZoryveRoflumilast | 42 | $42,566 |
| Clobetasol Propionate | 946 | $37,952 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonTremfya | $226,800 | $630,29346 claims |
| AbbVieSkyrizi | $198,722 | $229,47411 claims |
| E.r. Squibb & Sons, L.L.C.Sotyktu | $51,434 | $179,67022 claims |
| AmgenOtezla | $77,139 | $82,35917 claims |
| LEO Pharma Inc.Adbry | $36,576 | $68,19818 claims |
| Arcutis Biotherapeutics, Inc.Zoryve | $504 | $42,56642 claims |
| Incyte CorporationOpzelura | $51,476 | $30,22515 claims |
| Dermavant Sciences, Inc.Vtama | $2,961 | $25,66418 claims |
| Almirall LLCKlisyri | $94 | $17,66616 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,147 dermatology providers in Florida.
Other dermatology in Stuart
- Francisco KerdelMiami$2.1M
- Brad GlickMargate$2M
- Robert KirsnerMiami$1.4M
- Gil YosipovitchMiami$1M
- Shino Bay AguileraFt Lauderdale$1M
- Robert SnyderPembroke Pines$1M
- Marc IngleseTallahassee$989K
- Jeremy GreenCoral Gables$952K
- Mercedes GonzalezMiami$943K
- Andrew DorizasWest Palm Beach$897K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.